Anti-Glaucoma Medications

Overview

Every topical or oral glaucoma medication lowers intraocular pressure (IOP) through one of two mechanisms: reducing the ciliary body's production of aqueous humor, or increasing its outflow through the trabecular meshwork (conventional pathway) or the uveoscleral route (unconventional pathway). IOP is the only modifiable risk factor for glaucomatous optic neuropathy. Drug selection, at bottom, is a question of which mechanism, or combination of mechanisms, gets a given patient to their individualized target pressure with the fewest side effects.

Six drug classes are in routine use: prostaglandin analogs, beta-blockers, alpha-2 adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists (miotics), and rho-kinase inhibitors. Prostaglandin analogs have become the default starting point for most patients; the rest get reached for based on contraindications, additional IOP-lowering need, or tolerability.

Drug Classes

Prostaglandin Analogs

Prostaglandin F2-alpha analogs (latanoprost, bimatoprost, travoprost, tafluprost, and the nitric-oxide-donating latanoprostene bunod) bind FP receptors in the ciliary muscle and trigger matrix metalloproteinase-mediated remodeling of its extracellular matrix. That remodeling drives the increase in uveoscleral (unconventional) outflow behind their roughly 25–35% IOP reduction. Latanoprost itself is dosed as an inactive isopropyl ester prodrug; corneal esterases hydrolyze it into the active latanoprost acid before it reaches the ciliary muscle.

Two variants are worth knowing individually. Tafluprost is available preservative-free in unit-dose vials, useful for patients with significant ocular surface disease or benzalkonium chloride (BAK) sensitivity. Latanoprostene bunod is metabolized into both latanoprost acid (increasing uveoscleral outflow via FP receptors) and a nitric oxide donor that activates the guanylyl cyclase/cGMP pathway in trabecular meshwork cells, relaxing them and increasing conventional outflow as well. It is the only prostaglandin analog that lowers IOP through both outflow pathways at once.

The class's defining side effect is permanent and dose-independent: increased melanin synthesis in iris stromal melanocytes darkens the iris and periorbital skin, most noticeable in hazel and blue-brown eyes. The same follicle-stimulating effect that darkens periocular skin also lengthens and thickens eyelashes, a side effect marketed outright as bimatoprost for hypotrichosis. Patients should be counseled on both before starting therapy: the iris color change does not reverse after the drug is stopped.

Beta-Blockers

Topical beta-blockers, timolol being the prototype, block beta-2 adrenoceptors on the ciliary epithelium, reducing cAMP-mediated aqueous secretion by roughly 20–25%. They have no meaningful effect on outflow. Betaxolol is cardioselective (beta-1 predominant), which lowers its bronchospasm risk in patients with mild reactive airway disease. Because both beta-1 and beta-2 blockade at the ciliary body contribute to aqueous suppression, though, betaxolol ends up less effective at lowering IOP than non-selective timolol.

The contraindications follow from systemic absorption via the nasolacrimal duct into the systemic circulation, bypassing first-pass hepatic metabolism. Non-selective beta-blockers can precipitate bronchospasm in asthma or COPD through beta-2 blockade in airway smooth muscle, and can cause bradycardia, hypotension, or heart block in patients with pre-existing conduction disease.

Alpha-2 Adrenergic Agonists

Brimonidine, the class's main representative, lowers IOP through two complementary mechanisms at once: it inhibits adenylate cyclase in the ciliary epithelium to reduce aqueous production, and modestly increases uveoscleral outflow. Together these account for roughly a 20–25% reduction.

Brimonidine is generally avoided in infants and young children: their still-immature blood-brain barrier lets the drug cross more readily, and it can cause central nervous system and respiratory depression, bradycardia, hypotension, and even apnea. That pediatric safety concern does not apply to any other first-line glaucoma drug class.

Carbonic Anhydrase Inhibitors (CAIs)

Both the topical agents (dorzolamide, brinzolamide) and the oral agent (acetazolamide) work the same way: inhibiting carbonic anhydrase II in the ciliary epithelium reduces bicarbonate-dependent sodium and fluid transport into the posterior chamber, cutting aqueous production by roughly 30%.

Oral acetazolamide carries the class's most clinically significant side effects. Renal bicarbonate wasting produces a mild hyperchloremic metabolic acidosis, which manifests as the classic paresthesias (tingling fingers and toes), along with fatigue and polyuria. Reduced urinary citrate and elevated urinary pH increase the risk of calcium phosphate kidney stones, so acetazolamide is used cautiously in patients with a prior stone history. Rarely, and independent of dose, systemic CAIs can cause aplastic anemia or agranulocytosis as an idiosyncratic sulfonamide reaction; topical CAIs carry a much lower but non-zero version of the same risk through systemic absorption.

Cholinergic Agonists (Miotics)

Pilocarpine, the classic direct-acting cholinergic agonist, contracts the ciliary muscle. That contraction pulls on the scleral spur, mechanically widening the spaces within the trabecular meshwork and enhancing conventional outflow. Among these classes it is the one that acts by traction on the meshwork, whereas the others act on production, the uveoscleral pathway, or (netarsudil) the meshwork cells directly.

Its side effects come from the same ciliary muscle contraction: accommodative spasm and induced myopia, along with miosis-related dim vision and brow ache. These limit its use in younger patients with active accommodation, and pilocarpine has largely been supplanted by better-tolerated classes for chronic therapy. It retains a role in acute angle-closure management, though, where miosis itself is therapeutic.

Rho-Kinase Inhibitors

Netarsudil, the first FDA-approved rho-kinase (ROCK) inhibitor for glaucoma, works differently from every class above. It is the only drug that directly targets the trabecular meshwork and Schlemm's canal cells themselves, relaxing their cytoskeleton and increasing conventional outflow facility. As a dual ROCK and norepinephrine transporter inhibitor, it also reduces episcleral venous pressure and contributes a smaller reduction in aqueous production.

Fixed-Combination Therapy

When two mechanisms are needed, fixed-combination drops pair agents from different classes into a single bottle. Dorzolamide-timolol (CAI + beta-blocker) is the prototype, combining two production-reducing mechanisms for an additive effect. Beyond convenience, fixed combinations improve adherence by reducing the number of daily instillations, and cut the patient's total daily exposure to preservatives like BAK.

Brimonidine-timolol pairs an alpha-2 agonist with a beta-blocker instead of two production-reducing drugs. Timolol still suppresses aqueous production, but brimonidine adds a second mechanism on top of its own production-lowering effect: a modest increase in uveoscleral outflow, giving the combination a mixed rather than purely additive-production profile.

Choosing & Sequencing Therapy

Prostaglandin analogs are favored as first-line therapy for newly diagnosed primary open-angle glaucoma without contraindications, on the strength of once-nightly dosing, strong efficacy, and minimal systemic absorption compared to every other class.

Target IOP is not a fixed number. It is individualized primarily to the severity of existing glaucomatous optic nerve damage, along with baseline IOP and rate of progression, and more advanced damage generally demands a lower target to prevent further vision loss.

When a patient on maximally tolerated monotherapy still progresses despite adequate IOP lowering, the usual next step is switching to a different drug class rather than adding a second medication outright. The goal is finding the single most effective monotherapy before committing to combination treatment.

Selective laser trabeculoplasty (SLT) has also become a legitimate first-line alternative to drops rather than a fallback after medication failure. The LiGHT trial demonstrated that SLT offers IOP control comparable to topical therapy, with fewer patients needing subsequent incisional surgery.

High-Yield Pearls

• Prostaglandin analogs: first-line, once-nightly, ↑ uveoscleral outflow via FP-receptor-mediated ciliary muscle remodeling; permanent iris darkening, plus periocular darkening and eyelash growth.
• Betaxolol is cardioselective and safer in reactive airway disease than timolol, but weaker at lowering IOP.
• Brimonidine is avoided in infants: immature blood-brain barrier risks CNS/respiratory depression and apnea.
• Oral acetazolamide: metabolic acidosis, paresthesias, calcium phosphate stones, and rare aplastic anemia as an idiosyncratic sulfonamide reaction.
• Netarsudil is the only class that directly targets the trabecular meshwork/Schlemm's canal cytoskeleton.
• Two separate drops need ≥5 minutes apart to avoid washout.